Kobo Biotech Ltd. is significantly underperforming compared to its peers in the Pharmaceuticals & Drugs sector, exhibiting negative growth, poor profitability metrics, and extremely high debt levels. This positions it as a laggard in both financial health and market valuation.

• • Kobo Biotech has negative revenue growth and EPS, indicating operational difficulties.
• • High debt-to-equity ratio (3.38) suggests financial distress compared to peers with low ratios.
• • Despite low valuation metrics, Kobo's negative profitability makes it unattractive as a value pick.